AI assistant
Sending…
LIGAND PHARMACEUTICALS INC — Director's Dealing 2016
Jul 6, 2016
31289_dirs_2016-07-05_15926ce6-faf5-4fc6-804e-33c3d92fae49.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2016-06-30
Reporting Person: Korenberg Matthew E (VP, Finance and CFO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-06-30 | Common Stock | J | 196.0 | $87.0995 | Acquired | 10066 | Direct |
Footnotes
F1: Shares acquired under Ligand's employee stock purchase plan. Voluntary reporting exemption under Rule 16b-3(c).
More from LIGAND PHARMACEUTICALS INC
Proxy Solicitation & Information Statement
2026
May 18
M&A Activity
2026
May 18
Interim / Quarterly Report
2026
May 8
Earnings Release
2026
May 7
Major Shareholding Notification
2026
May 1
Major Shareholding Notification
2026
May 1
Regulatory Filings
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 27
M&A Activity
2026
Apr 27
Annual Report
2026
Apr 21